PARP and Aurora kinase combo therapy for advanced prostate cancer
Official title: The synergy of PARP inhibition plus Aurora kinase inhibition in advanced prostate cancer therapy.
Funded at Mayo Clinic Rochester · NIH-11334073 · Data updated 2026-11-12
A Mayo Clinic researcher is testing whether combining PARP inhibitors with Aurora kinase inhibitors can better treat advanced prostate cancer in men.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 18, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $224,314 |
| NIH project number | 1P50CA298941-01A1 |
| Project ID | NIH-11334073 on NIH RePORTER |
Who could benefit from this research
✓Could help
American men with advanced/metastatic prostate cancer who have progressed on standard ARPI or PARPi therapies could be eligible.
✕Less likely to help
Patients with cancers not driven by PARP or Aurora kinase pathways or those unable to tolerate combination therapy may not benefit.
What this research studies
This grant supports studies in patients with advanced prostate cancer to see if blocking PARP and Aurora kinase at the same time can overcome resistance to current therapies. The approach aims to sensitize cancer cells to PARPi and may extend the time before progression. The research uses established models and early human data to guide combination strategies and may inform future clinical trials. Participants could potentially benefit if the combination proves more effective or tolerable than today’s options.
Why it matters
Potential benefit: If successful, the combination could improve response and survival for men with advanced prostate cancer.
How similar studies have gone: PARP inhibitors have shown benefit in HRR-deficient prostate cancer, and preclinical data suggest combination strategies may enhance efficacy.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Wang, Liewei — Mayo Clinic Rochester
- Study coordinator: Wang, Liewei
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.